Denmark's Novo Nordisk To Double R&D Workforce In China
This article was originally published in PharmAsia News
The Danish healthcare company says it plans to increase the workforce in its Beijing research and development center from 100 to 200 by 2015, aimed primarily at staffing a new Diabetes Research Unit
You may also be interested in...
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.